The Healthcare Standard

Analyzing Health Insurance Innovations, Inc. (HIIQ) From Top to Bottom

On Friday, shares of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) marked $18.57 per share versus a previous $19.75 closing price. With having a -5.97% loss, an insight into the fundamental values of Health Insurance Innovations, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. HIIQ showed a fall of -30.53% within its YTD performance, with highs and lows between $15.95 – $46.60 during the period of 52 weeks, compared to the simple moving average of -20.67% in the period of the last 200 days.

Raymond James equity researchers changed the status of Health Insurance Innovations, Inc. (NASDAQ: HIIQ) shares from “Outperform” to a “Mkt Perform” rating in the report published on November 18th, 2019. Other analysts, including B. Riley FBR, also published their reports on HIIQ shares. B. Riley FBR repeated the rating from the previous report, marking HIIQ under “Buy” rating, in the report published on March 18th, 2019. Additionally, HIIQ shares got another “Neutral” rating from B. Riley FBR, setting a target price of $45 on the company’s shares, according to the report published in February 27th, 2019. On October 31st, 2018, Lake Street Reiterated an Buy rating and increased its price target from $51 to $75. On the other hand, First Analysis Sec Upgrade the “Strong Buy” rating for HIIQ shares, as published in the report on October 29th, 2018. Raymond James seems to be going bullish on the price of HIIQ shares, based on the price prediction for HIIQ. Another “Buy” rating came from B. Riley FBR, Inc., providing a prediction for price target according to the report published in February 13th, 2018.

 

Read more…

The Healthcare Standard

Obesity May Boost Effectiveness of a Lung Cancer Therapy

MONDAY, Dec. 30, 2019 (HealthDay News) — Obesity is seldom a friend to health, but in one medical context it might give patients a slight advantage, new research suggests.

Specifically, when Australian researchers looked at trials of atezolizumab, an immune system-based treatment for lung cancer, they found that the drug worked better in people who were overweight.

The trial involved more than 2,100 people with the most common form of lung tumors, non-small cell lung cancer. About half of the participants were normal weight, about one-third were overweight and 7 percent were obese. About two-thirds of patients received the newer drug, atezolizumab, while the remaining third got an older drug, docetaxel.

The researchers found that obesity — a body mass index (BMI) of 30 or above — “was associated with significantly improved overall survival in patients treated with atezolizumab, but not in those who received docetaxel.”

 

Read more…

The Healthcare Standard

Hospital group mum as members pursue patients with lawsuits, debt collectors

The American Hospital Association, the biggest hospital trade group, says it promotes “best practices” among medical systems to treat patients more effectively and improve community health.

But the powerful association has stayed largely silent about hospitals suing thousands of patients for overdue bills, seizing homes or wages and even forcing families into bankruptcy.

Atlantic Health System, whose CEO is the AHA’s chairman, Brian Gragnolati, has sued patients for unpaid bills thousands of times this year, court records show, including a family struggling to pay bills for three children with cystic fibrosis.

AHA, which represents nearly 5,000, mostly nonprofit hospitals and medical systems, has issued few guidelines on such aggressive practices or the limited financial assistance policies that often trigger them.

 

Read more…

The Healthcare Standard

New Technology May Help in Diagnosis of Pancreatic Cancer

Recently, research focusing on the use of newly developed technology for the detection of cancerous tumors in the pancreas has been successfully used for diagnosis with high accuracy. A team of researchers at Ohio State University Wexner Medical Center led by Dr. Somashekar Krishna.

According to Dr. Krishna, who is an endocrinologist, only nine percent of the patients survive five years after they are given a diagnosis of pancreatic cancer. This is because cancerous tumors in the pancreas are typically hard to detect. By the time doctors are able to diagnose cancer, it has often reached a stage where the majority of the treatments do not work and the patient has only limited options.

Usually, pancreatic cancer produces no symptoms. Therefore, most of the health professionals are not able to diagnose it even after a physical examination. Advance stage pancreatic cancer comes with a number of different symptoms including blood clot formation, dark colored urine, unexplained weight loss, fatigue, itchy skin, loss of appetite, signs similar to jaundice such as yellow hues in eyes, lips, and skin, and increased difficulty in controlling blood sugar and diabetes or getting a new diagnosis of diabetes.

 

Read more…

The Healthcare Standard

Royal News: Princess Anne Tears Into ‘Health and Safety’ Children Need The ‘Risk Element’

The royal warned that PC culture is preventing kids from learning the vital “skills” necessary to assess risks and make decisions themselves. She said: “If you don’t allow children to assess their own risk-taking abilities, they never really learn. “So they then go off and do things, which inherently they’re not good enough to do, but somebody has said health and safety says this is OK, and they have got no way of judging on their own whether or not they’ve got the skills to do it.”

A famously sporty individual, the royal won a haul of European gold and silver medals through her equestrian career.

Continuing she said: “One of the things that all sports have to come to terms with is the risk element.

 

Read more…

The Healthcare Standard

Opinion: It’s Time To End The Colonial Mindset In Global Health

Today, the field of “global health” strives to create equitable and just relationships between wealthy and impoverished regions, places and peoples. But it is still a field with markedly unequal power dynamics: racism, classism and many of the residual exploitations of a terrible colonial past. I fear that this point often goes missed or ignored, possibly because we are subconsciously or consciously engaged in a neocolonial narrative in which wealthy people are “saving” poor people even as they build their own careers.

It is not a relationship in which Western visitors and local people are collaborating equally — or perhaps even more appropriately, where local leaders take the dominant role.

I’m currently doing a diploma course in tropical medicine. There were lectures on AIDS, malaria and tuberculosis treatment and on noncommunicable diseases like diabetes and hypertension in Africa,

 

Read more…

The Healthcare Standard

Hastings council leaders expected to bid for £25 million government funding

Hastings Borough Council could be set to bid for up to £25m of government funding, if the first phase is approved by council leaders next week.

At a meeting on Monday (January 6), Hastings Borough Council’s cabinet are expected to give the go ahead to begin developing a formal ‘town deal bid’, which would seek to secure government funding to improve the local economy.

This would see council leaders agree to set up a board tasked with developing an investment plan for the town, which would highlight areas where investment could make a difference. This work will be funded through a £173,029 grant provided by government.

 

Read more…

The Healthcare Standard

Georgia’s Key Health Care Stories Of 2019 | 90.1 FM WABE

From waivers to toxic pollution to disease outbreaks, Georgia had an eventful year in health care. Here is our list of the Top 10 health care stories in 2019.

1. Gov. Brian Kemp unveiled proposals to offer more people Medicaid coverage and improve private insurance.

Just as 2019 ended, the Kemp administration finalized its health care proposals, which will require approval by the feds. One waiver request would add more low-income Georgians to Medicaid. Democrats repeatedly emphasized that the plan’s eligibility requirements would cover far fewer people than Medicaid expansion under the Affordable Care Act. But Kemp and his fellow Republicans who control state government made clear that their opposition to Medicaid expansion had not changed. A second waiver proposal calls for a ‘‘reinsurance’’ program, plus a plan to replace the state’s current healthcare.gov website procedure with what officials say would be a more consumer-friendly enrollment process.

 

Read more…

The Healthcare Standard

Why Amazon Makes A Big Pharmacy Move In 2020

The PillPack website is displayed in Washington, D.C., June 28, 2018 when Amazon agreed to buy the … [+] online pharmacy.

Amazon is quietly talking to health insurance companies about new ways to integrate its online pharmacy services into their medical plans and employer health benefits.

The online retail giant, working under the PillPack by Amazon pharmacy brand rolled out in the last year, is winning over health insurers through their health plan enrollees.

Take Blue Cross Blue Shield of Massachusetts, which is working with Pillpack to integrate pharmacy services in the insurer’s app and website, in the kind of deal that could be a boon of new customers for the online pharmacy. The Massachusetts Blues plan said it was the first health plan to offer such “direct integration” and they did so because PillPack by Amazon’s services were so popular with Blue Cross health plan enrollees.

 

Read more…

The Healthcare Standard

Wipeout In Wave Life Sciences

Wave Life Sciences closed down over 55% on Dec. 16 after the company announced that it planned to halt development of its exon-skipping DMD treatment suvodirsen.

While the news trimmed over 713 million from the company’s market cap, its enterprise value remains at nearly 387 million with $5.11 per share in cash after backing out debt.

As of the end of third quarter of this year, Wave, once the largest single holding of Peter Kolchinsky’s RA Capital hedge fund, still accounted for 9.33% of the fund.

Now that their lead drug in development has been shut down, the company’s pipeline just consists of two Hungtinton’s compounds in Phase 1b/2a and several pre-clinical candidates.

 

Read more…